Miura K - Search Results

1

Impact of a blood-stage vaccine on Plasmodium vivax malaria.

Hou MM, Barrett JR, Themistocleous Y, Rawlinson TA, Diouf A, Martinez FJ, Nielsen CM, Lias AM, King LDW, Edwards NJ, Greenwood NM, Kingham L, Poulton ID, Khozoee B, Goh C, Mac Lochlainn DJ, Salkeld J, Guilotte-Blisnick M, Huon C, Mohring F, Reimer JM, Chauhan VS, Mukherjee P, Biswas S, Taylor IJ, Lawrie AM, Cho JS, Nugent FL, Long CA, Moon RW, Miura K, Silk SE, Chitnis CE, Minassian AM, Draper SJ. Hou MM, et al. Among authors: miura k. medRxiv [Preprint]. 2022 May 30:2022.05.27.22275375. doi: 10.1101/2022.05.27.22275375. medRxiv. 2022. Update in: Sci Transl Med. 2023 Jul 12;15(704):eadf1782. doi: 10.1126/scitranslmed.adf1782. PMID: 35664997 Free PMC article. Updated. Preprint.

2

Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.

Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A. Malkin EM, et al. Among authors: miura k. Vaccine. 2005 May 2;23(24):3131-8. doi: 10.1016/j.vaccine.2004.12.019. Vaccine. 2005. PMID: 15837212 Free PMC article. Clinical Trial.

3

Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.

Singh S, Miura K, Zhou H, Muratova O, Keegan B, Miles A, Martin LB, Saul AJ, Miller LH, Long CA. Singh S, et al. Among authors: miura k. Infect Immun. 2006 Aug;74(8):4573-80. doi: 10.1128/IAI.01679-05. Infect Immun. 2006. PMID: 16861644 Free PMC article.

4

Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.

Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, Saul A. Miura K, et al. Malar J. 2007 Aug 8;6:107. doi: 10.1186/1475-2875-6-107. Malar J. 2007. PMID: 17686163 Free PMC article.

5

In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized.

Miura K, Zhou H, Muratova OV, Orcutt AC, Giersing B, Miller LH, Long CA. Miura K, et al. Infect Immun. 2007 Dec;75(12):5827-36. doi: 10.1128/IAI.00593-07. Epub 2007 Oct 8. Infect Immun. 2007. PMID: 17923516 Free PMC article.

6

Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines.

Miura K, Orcutt AC, Muratova OV, Miller LH, Saul A, Long CA. Miura K, et al. Vaccine. 2008 Jan 10;26(2):193-200. doi: 10.1016/j.vaccine.2007.10.064. Epub 2007 Nov 20. Vaccine. 2008. PMID: 18054414 Free PMC article.

7

Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.

Mullen GE, Ellis RD, Miura K, Malkin E, Nolan C, Hay M, Fay MP, Saul A, Zhu D, Rausch K, Moretz S, Zhou H, Long CA, Miller LH, Treanor J. Mullen GE, et al. Among authors: miura k. PLoS One. 2008 Aug 13;3(8):e2940. doi: 10.1371/journal.pone.0002940. PLoS One. 2008. PMID: 18698359 Free PMC article. Clinical Trial.

8

Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination.

Miura K, Zhou H, Moretz SE, Diouf A, Thera MA, Dolo A, Doumbo O, Malkin E, Diemert D, Miller LH, Mullen GE, Long CA. Miura K, et al. J Immunol. 2008 Dec 15;181(12):8776-83. doi: 10.4049/jimmunol.181.12.8776. J Immunol. 2008. PMID: 19050299 Free PMC article. Clinical Trial.

9

A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.

Ellis RD, Mullen GE, Pierce M, Martin LB, Miura K, Fay MP, Long CA, Shaffer D, Saul A, Miller LH, Durbin AP. Ellis RD, et al. Among authors: miura k. Vaccine. 2009 Jun 24;27(31):4104-9. doi: 10.1016/j.vaccine.2009.04.077. Epub 2009 May 15. Vaccine. 2009. PMID: 19410624 Free PMC article. Clinical Trial.

10

Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.

Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, Miller LH, Martin LB, Pierce MA, Ellis RD, Mullen GE, Long CA. Miura K, et al. Clin Vaccine Immunol. 2009 Jul;16(7):963-8. doi: 10.1128/CVI.00042-09. Epub 2009 May 13. Clin Vaccine Immunol. 2009. PMID: 19439523 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,729 results

Search Page

Filters